Gemcitabine/Paclitaxel (Duo Oncology)

吉西他滨/紫杉醇 (Duo Oncology)

Report date: 2025/11/07 14:58:39

Base Information

Drug NameGemcitabine/Paclitaxel (Duo Oncology)

Drug Alias Namepaclitaxel / polyoligo(ethylene glycol)methacrylate-co-poly(vinylbenzyldithiodibutyric acid-gemcitabine)copolymer-conjugated gemcitabine encapsulating paclitaxelDUO-207

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionTubulin polymerisation promotersTubulin depolymerization inhibitorsRibonucleotide reductase inhibitors +[4]

TargetsTubulinRibonucleotide reductaseDNA

Therapy Area/IndicationsPancreatic NeoplasmsBiliary Tract Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsYes

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesDuo Oncology Europe BV

China Registration ClassN/A

Develop Information

Active CompaniesDuo Oncology Europe BV

Inactive CompaniesN/A

Active IndicationsPancreatic NeoplasmsBiliary Tract Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A